The Hospital Authority of Metropolitan Government of Nashville and Davidson County, Tennessee v. Momenta Pharmaceuticals, Inc. et al
Case Number:
3:15-cv-01100
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Alston & Bird
- Axinn Veltrop
- Bass Berry
- Choate Hall
- Fish & Richardson
- Lieff Cabraser
- Riley & Jacobson
- Spragens Law
- Wilson Sonsini
Companies
- American Federation of State County & Municipal Employees
- Amphastar Pharmaceuticals Inc.
- Fresenius Kabi AG
- Fresenius SE & Co. KGaA
- Momenta Pharmaceuticals Inc.
- Sandoz International GmbH
Sectors & Industries:
-
June 01, 2020
Lieff Cabraser Snags $40M Fees From Sandoz, Momenta Deal
Lieff Cabraser Heimann & Bernstein LLP and a former firm associate have won $40 million in fees from a $120 million deal they helped hospitals, health insurers and uninsured consumers ink with Sandoz and Momenta over the price of generic blood thinners.
-
December 11, 2019
Momenta To Pay $35M To Exit Blood Clot Drug Antitrust Suit
Momenta has agreed to pay $35 million to exit a class action brought by a group of drug buyers accusing the company and Sandoz of conspiring to monopolize the blood clot drug Lovenox and its generic version.
-
October 22, 2019
Momenta, Sandoz Can't Pause Blood-Clot Drug Antitrust Suit
A Tennessee federal judge refused Monday to pause a lawsuit that accuses Momenta and Sandoz of conspiring to monopolize the blood-clot drug Lovenox and its generic version while they appeal the certification of a class of thousands of drug buyers, prompting the companies to seek emergency Sixth Circuit intervention Tuesday.
-
October 03, 2019
Momenta, Sandoz Try To Pause Blood-Clot Drug Antitrust Suit
Momenta and Sandoz have urged a Tennessee federal judge to pause a lawsuit accusing them of conspiring to monopolize blood-clot drug Lovenox and its generic version while they appeal the certification of a class of thousands of drug buyers.
-
September 20, 2019
Buyers Win Class Cert. In Blood Clot Drug Monopoly Suit
A Tennessee federal judge on Friday certified a class of thousands of Lovenox buyers in a suit from a Nashville hospital and a union health plan accusing Momenta and Sandoz of conspiring to monopolize the blood clot drug and its generic version.
-
September 16, 2019
Momenta, Sandoz Push For Sanctions In Blood Clot Drug Suit
Momenta and Sandoz have urged a Tennessee federal court to sanction a hospital accusing them of conspiring to monopolize the blood clot drug Lovenox and its generic version for allegedly not properly preserving certain billing records, a move the hospital called a distraction.
-
May 16, 2019
Blood Clot Drug Buyers Must Redo Class Cert. Bid
Nashville's general hospital has one week to amend a proposed class of Lovenox buyers after a Tennessee federal judge rejected a last-minute tweak to the class definition in a lawsuit accusing Momenta and Sandoz of conspiring to monopolize the blood clot drug and its generic version.
-
December 06, 2018
Sherman Act Cut From Clot Drug Suit, State Claims Survive
A Tennessee federal judge has freed Momenta Pharmaceuticals Inc. and Sandoz Inc. from Sherman Act allegations that they conspired to monopolize the market for the blood clot drug Lovenox and its generic version, but kept related state claims alive.
-
November 19, 2018
Blood-Clot Drug Buyers Seek Class Cert. In Antitrust Suit
Indirect purchasers of blood clot drug Lovenox and its generic version asked a Tennessee federal court for class certification in their suit alleging Momenta Pharmaceuticals Inc. and Sandoz Inc. conspired to monopolize the market for the medication.
-
February 16, 2018
Momenta, Sandoz Can't Nix Drug Antitrust Suit, Court Told
A Tennessee hospital urged a federal court Thursday to keep its antitrust lawsuit against Momenta Pharmaceuticals Inc. and Sandoz Inc. alive because a related challenge to a Momenta patent is ongoing.